COVID-19 vaccines in patients with cancer
暂无分享，去创建一个
[1] M. Malim,et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study , 2021, The Lancet Oncology.
[2] The Lancet Oncology,et al. COVID-19 and cancer: 1 year on , 2021, The Lancet Oncology.
[3] D. Gurdasani,et al. Delaying the second dose of covid-19 vaccines , 2021, BMJ.
[4] T. Choueiri,et al. COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials , 2021, Nature Reviews Clinical Oncology.
[5] C. M. Saad-Roy,et al. Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes , 2021, Science.
[6] D. Ho,et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7 , 2021, Nature.
[7] C. M. Saad-Roy,et al. Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes , 2021, medRxiv.
[8] D. Ho,et al. Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 , 2021, bioRxiv.
[9] G. Curigliano,et al. Commentary: SARS-CoV-2 vaccines and cancer patients , 2021, Annals of Oncology.
[10] Carl A. B. Pearson,et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England , 2021, Science.
[11] K. Salako,et al. On the reliability of predictions on Covid-19 dynamics: A systematic and critical review of modelling techniques , 2020, Infectious Disease Modelling.